(Q48256822)

10 February 2018

title

Laquinimod prevents inflammation-induced synaptic alterations occurring in experimental autoimmune encephalomyelitis. (English)

1 reference

10 February 2018

experimental autoimmune encephalomyelitis

main subject

0 references

0 references

2

1 reference

10 February 2018

Diego Centonze

12

1 reference

10 February 2018

Valeria Studer

object named as

Valeria Studer

7

0 references

Giacomo P Comi

11

object named as

Giancarlo Comi

1 reference

10 February 2018

Francesca Ruffini

1

1 reference

10 February 2018

Andrea Bergamaschi

3

1 reference

10 February 2018

Elena Brambilla

4

1 reference

10 February 2018

Annamaria Finardi

5

1 reference

10 February 2018

Caterina Motta

6

1 reference

10 February 2018

Francesca Barbieri

8

1 reference

10 February 2018

Valentina De Chiara

9

1 reference

10 February 2018

Liat Hayardeny

10

1 reference

10 February 2018

Gianvito Martino

13

1 reference

10 February 2018

publication date

11 December 2012

1 reference

10 February 2018

Multiple Sclerosis Journal

published in

1 reference

10 February 2018

volume

19

1 reference

10 February 2018

issue

8

1 reference

10 February 2018

page(s)

1084-1094

1 reference

10 February 2018

https://api.crossref.org/works/10.1177%2F1352458512469698

1 reference

Transient axonal injury in the absence of demyelination: a correlate of clinical disease in acute experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512469698

Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512469698

Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512469698

The link between inflammation, synaptic transmission and neurodegeneration in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512469698

In vivo imaging of partially reversible th17 cell-induced neuronal dysfunction in the course of encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512469698

Inflammation in neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512469698

Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512469698

Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512469698

Impaired striatal GABA transmission in experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512469698

The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512469698

The endocannabinoid system in the inflammatory and neurodegenerative processes of multiple sclerosis and of amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512469698

Abnormal activity of the Na/Ca exchanger enhances glutamate transmission in experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512469698

Axonal pathology in multiple sclerosis: relationship to neurologic disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512469698

Brain atrophy in clinically early relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512469698

Measurement of spinal cord area in clinically isolated syndromes suggestive of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512469698

Cannabinoid control of neuroinflammation related to multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512469698

Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512469698

Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512469698

Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512469698

Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512469698

Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512469698

The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512469698

Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512469698

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512469698

Placebo-controlled trial of oral laquinimod for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512469698

21 January 2018

Identifiers

DOI

10.1177/1352458512469698

1 reference

10 February 2018

1 reference

10 February 2018